News Release

Bridging aging research and artificial intelligence

First longevity biotechnology company to be included in global top 100 AI companies list

Grant and Award Announcement

Biogerontology Research Foundation

The UK-based Biogerontology Research Foundation (BGRF), which seeks to apply scientific knowledge of aging to the diseases and debilities of old age, proudly salutes its director and trustee Alex Zhavoronkov PhD, whose aging and drug discovery company Insilico Medicine has been included in the prestigious AI 100 list for 2018, announced by CB Insights this month. These are a select group of private companies working on groundbreaking artificial intelligence technology.

"Last year's AI 100 enjoyed amazing success in the year since earning this recognition. 55 of them went on to raise additional funding nearing $2B and 5 were acquired. This year's list was culled from 1000+ applications and looks even more impressive. These are companies using artificial intelligence in industries from drug discovery and cybersecurity to robotics and legal tech. I'm happy that CB Insights is able to shine a light on the founders and companies that will revolutionize these industries and look forward to seeing what they do in 2018 and beyond." said CB Insights CEO Anand Sanwal.

The CB Insights research team used an evidence-based, statistically-driven approach, known as the Mosaic Score, to make a selection based on a company's momentum, market health and financial viability.

BGRF recognises the relevance of AI to biotechnology, an industry increasingly reliant on big data.

"In 2014 Insilico Medicine made a bet on the deep learning technology and since then established over 250 industry and academic collaborations in both drug discovery and biomarker development and we became an innovation driver for the pharmaceutical industry. We are very happy to be recognized as one of the top 100 global AI companies by CB Insights, one of the top industry analysts," said Zhavoronkov.


About Alex Zhavoronkov

Alex Zhavoronkov PhD, is the director and a trustee of the Biogerontology Research Foundation. He heads the laboratory of regenerative medicine at the Clinical Research Center for Pediatric Hematology, Oncology and Immunology where his research interests include Hutchinson-Gilford Syndrome, new methods of cellular reprogramming, molecular mechanisms of skin and cartilage regeneration and personalized medicine in oncology. He is also the international adjunct professor at the Moscow Institute of Physics and Technology. He is the CEO and co-founder of InSilico Medicine, Inc., a Baltimore-based company utilizing Big Data analysis for aging research and drug discovery. Dr Zhavoronkov is the author of multiple peer-reviewed scientific as well as popular papers and books on the many aspects of biogerontology, aging research and aging economics including "The Ageless Generation: how biomedical advances will transform the global economy" published by Palgrave Macmillan. He holds two bachelor degrees from Queen's University, a masters in biotechnology from Johns Hopkins Universtity and a PhD in physics and mathematics from the Moscow State University.

About CB Insights

Builds technology that helps corporations guess less and win more. Aggregates and analyze terabytes of data and use machine learning, algorithms and data visualization to help corporations replace the three Gs (Google searches, gut instinct and guys with MBAs) so they can answer massive strategic questions using probability not punditry.


Farrah Kim
Senior Public Relations & Communications Manager

For more information about the AI 100, visit:

About Insilico Medicine, Inc

Insilico Medicine, Inc. is an artificial intelligence company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore, with R&D resources in Belgium, Russia, and the UK sourced through hackathons and competitions.

The company utilizes advances in genomics, big-data analysis, and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. The company is pursuing internal drug discovery programs in cancer, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging.

Through its Pharma.AI division, Insilico provides advanced machine learning services to biotechnology, pharmaceutical, and skin care companies, foundations and national governments globally. In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact.


Qingsong Zhu, PhD

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.